Antibodies are Y-shaped glycoproteins composed of two heavy (H) and two light (L) chains, with antigen-binding sites at the variable (Fab) region and effector functions mediated by the constant (Fc) region . Key features include:
Fab region: Binds antigens via hypervariable loops (complementarity-determining regions, CDRs).
Fc region: Engages immune cells (e.g., macrophages) via Fc receptors or activates complement .
Anti-peptide antibodies are critical tools for detecting linear epitopes in proteins. Examples include:
Target: Residues within APP outside the beta-amyloid domain .
Applications: Detects APP proteolytic fragments in Alzheimer's disease research .
Characteristics:
| Parameter | Detail |
|---|---|
| Host Species | Chicken (IgY) |
| Reactivity | Human APP |
| Concentration | 100 µg/mL |
| Applications | Western blot, ELISA, IHC |
Target: SPPL3, a protease involved in regulated intramembrane proteolysis .
Applications: Immunoprecipitation, western blot (validated in HEK293 lysates) .
Characteristics:
| Parameter | Detail |
|---|---|
| Clone | 7F9 (monoclonal) |
| Isotype | IgG1κ |
| Reactivity | Human |
| Applications | IP, western blot |
Third-generation anti-cyclic citrullinated peptide (anti-CCP3) antibodies exemplify peptide-targeted antibodies with clinical utility:
Predictive Value: Anti-CCP3 improves risk stratification for inflammatory arthritis (IA) in anti-CCP2-negative individuals .
| Parameter | Anti-CCP3+ (≥5 units) | Anti-CCP3− |
|---|---|---|
| IA Progression Risk | 48.4% | 9.8% |
| RA Progression Risk | 30.2% | 3.3% |
Mechanism: Binds citrullinated epitopes exposed during protein denaturation .
Epitope Accessibility: Denaturation (e.g., western blot) may alter epitopes, reducing antibody binding .
Validation: Peptide microarrays and chromatin immunoprecipitation (ChIP) are gold standards for specificity .